$1.150
-0.015 (-1.29%)Al cierre
Noticias de IMRN
Eventos de IMRN
Trump Administration Injects $150M into xLight
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.XLIGHT STAKE:The Trump administration has agreed to inject up to $150M into xLight, which makes lasers for EUV machines and has former IntelCEO Pat Gelsinger on its board, for an equity stake, The Wall Street Journal's Amrith Ramkumar and Robbie Whelan. ASMLis currently the only global producer of EUV machines, which can cost hundreds of millions of dollars each.AMICABLE SETTLEMENT:Trump Media and Technologyannounced that Trump Media and United Atlantic Ventures reached an "amicable" settlement of their dispute and all claims by Trump Media against United Atlantic Ventures have been mutually resolved.NEW DOD AWARD:Immuronannounced a new research agreement with the Naval Medical Research Command -NMRC - and the Walter Reed Army Institute of Research, or WRAIR, Silver Spring, MD, USA funded by a U.S. Department of Defense subaward.The Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel vaccines targeting Campylobacter jejuni and Shigella sonnei. Under a recently executed collaborative research agreement with the Henry M. Jackson Foundation, new vaccine preparations against these pathogens have been developed and formulated at the military research institutes and subsequently provided to Immuron.Immuron will produce two hyper-immune bovine colostrum products for pre-clinical evaluation, with the objective of advancing a combined colostrum-based therapeutic specifically designed for the U.S. military. Also, the Uniformed Services University topline results from its clinical trial evaluating the effectiveness of enterotoxigenic E. coli hyperimmune bovine colostrum in maintaining gut health during deployment and travel are anticipated to be announced at the end of next week. In P2TD study, IMM-124E - the active ingredient in Travelan - was delivered in 600 mg powder sachets and administered twice daily in a randomized, placebo-controlled trial.Infectious diarrhea is the most common illness reported by travelers visiting developing countries and among U.S. troops deployed overseas. In the last decade, several enteric pathogens have an increasing resistance to commonly prescribed antibiotics.
Immuron Signs New Research Agreement with Naval Medical Research Command
Immuron announced a new research agreement with the Naval Medical Research Command - NMRC - and the Walter Reed Army Institute of Research, or WRAIR, Silver Spring, MD, USA funded by a U.S. Department of Defense subaward.The Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel vaccines targeting Campylobacter jejuni and Shigella sonnei. Under a recently executed collaborative research agreement with the Henry M. Jackson Foundation, new vaccine preparations against these pathogens have been developed and formulated at the military research institutes and subsequently provided to Immuron. Immuron will produce two hyper-immune bovine colostrum products for pre-clinical evaluation, with the objective of advancing a combined colostrum-based therapeutic specifically designed for the US military. Also, the Uniformed Services University topline results from its clinical trial evaluating the effectiveness of enterotoxigenic E. coli hyperimmune bovine colostrum in maintaining gut health during deployment and travel are anticipated to be announced at the end of next week. In P2TD study, IMM-124E - the active ingredient in Travelan - was delivered in 600 mg powder sachets and administered twice daily in a randomized, placebo-controlled trial. Infectious diarrhea is the most common illness reported by travelers visiting developing countries and among US troops deployed overseas. In the last decade, several enteric pathogens have an increasing resistance to commonly prescribed antibiotics.
Immuron Receives FDA Approval for IND of IMM-529
Immuron is pleased to announce that the United States FDA has approved Immuron's Investigational New Drug application for IMM-529 and the Phase 2 clinical trial may proceed. The company plans to initiate a Phase 2 clinical trial for IMM-529 in individuals with Clostridioides difficile infection during the first half of 2026.
Immuron Files IND Application with FDA for Clinical Development of IMM-529
Immuron announced that it has submitted an Investigational New Drug, or IND, application to the FDA for clinical development of IMM-529. Under this new IND, Immuron is proposing the development of IMM-529 for treatment of Clostridioides difficile, or C. diff, infection, or CDI, and prevention of recurrent CDI, or rCDI. The Company plans to initiate a Phase 2 clinical trial for IMM-529 in individuals with Clostridioides difficile infection, or CDI, during the first half of 2026. Independent Market analysis conducted by Lumanity suggests that, pending demonstration of efficacy, IMM-529 could be positioned at the earliest point in the treatment algorithm permitted by payer guidelines. The Phase 2 clinical trial is expected to enroll both first episode and recurrent CDI patients. The estimated eligible population of patients would be approximately 98,000 individuals if IMM-529 is introduced as a treatment at the first recurrence stage. The increased incidence of antibiotic resistant 'superbugs' has amplified the use of broad-spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is disruption of the gastrointestinal microbiota, resulting in susceptibility to opportunistic pathogens, such as C. diff. Paradoxically, treatment of CDI also involves antibiotic use, and the heavy reliance on antibiotics to control C. diff does not allow for the gut flora to regenerate and predisposes the patient to relapsing CDI. To address this need, Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the treatment of CDI and prevention recurrent CDI. IMM-529 has been designed with antibodies that target the key essential virulence components of C. diff, with the potential to accelerate the clearance of CDI infection and support rapid restoration of healthy gut microbiota. This novel 3-target approach has yielded promising results in pre-clinical infection and relapse models, including Prevention of primary disease; Protection of disease recurrence and Treatment of primary disease. Importantly IMM-529 antibodies cross-react with whole cell lysates of many different human and animal strains of C. diff including hypervirulent strains.
Immuron Provides Update on Ongoing Projects
Immuron is pleased to provide shareholders with a brief update on progress with a number of projects. Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products. Travelan Clinical Study: Topline results from the Travelan clinical study conducted by Uniformed Services University are anticipated in October 2025. IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug application to the U.S. FDA for IMM-529 in mid-October 2025. ProIBS Commercial Launch: The Australian Launch of ProIBS is on track for Q4 of calendar year 2025. IMM-986 Pre-Clinical Progress: Initial pre-clinical research studies for IMM-986, targeting Vancomycin-resistant Enterococci, are anticipated to be completed by year-end 2025. Immuron is on track to exceed FY24 first quarter sales.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.